Your browser doesn't support javascript.
Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies.
Li, Shibo; Wu, Jianbo; Jiang, Weiyu; He, Haiyan; Zhou, Yunjiao; Wu, Wei; Gao, Yidan; Xie, Minxiang; Xia, Anqi; He, Jiaying; Zhang, Qianqian; Han, Yuru; Wang, Nan; Zhu, Guangqi; Wang, Qiujing; Zhang, Zheen; Mayer, Christian T; Wang, Kang; Wang, Xiangxi; Wang, Junqing; Chen, Zhenguo; Jiang, Shibo; Sun, Lei; Xia, Rong; Wang, Qiao.
  • Li S; Department of Infectious Disease, Zhoushan Hospital, Wenzhou Medical University, Zhoushan, China.
  • Wu J; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Jiang W; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • He H; Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China.
  • Zhou Y; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Wu W; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Gao Y; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Xie M; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Xia A; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • He J; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Zhang Q; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Han Y; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Wang N; Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Zhu G; Department of Infectious Disease, Zhoushan Hospital, Wenzhou Medical University, Zhoushan, China.
  • Wang Q; Department of Infectious Disease, Zhoushan Hospital, Wenzhou Medical University, Zhoushan, China.
  • Zhang Z; Department of Infectious Disease, Zhoushan Hospital, Wenzhou Medical University, Zhoushan, China.
  • Mayer CT; Experimental Immunology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Wang K; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Wang X; CAS Key Laboratory of Infection and Immunity, National Laboratory of Macromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • Wang J; Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Chen Z; Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
  • Jiang S; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Sun L; Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Institute of Infectious Disease and Biosecurity, Shanghai Frontiers Science Center of Pathogenic Microbes and Infection, School of Basic Medical Sciences, Fudan University, Shanghai, China.
  • Xia R; Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
  • Wang Q; Department of Transfusion Medicine, Shanghai Huashan Hospital, Fudan University, Shanghai, China.
J Med Virol ; 95(2): e28440, 2023 02.
Article in English | MEDLINE | ID: covidwho-2268814
ABSTRACT
Emergence of various circulating SARS-CoV-2 variants of concern (VOCs) promotes the identification of pan-sarbecovirus vaccines and broadly neutralizing antibodies (bNAbs). Here, to characterize monoclonal antibodies cross-reactive against both SARS-CoV-1 and SARS-CoV-2 and to search the criterion for bNAbs against all emerging SARS-CoV-2, we isolated several SARS-CoV-1-cross-reactive monoclonal antibodies (mAbs) from a wildtype SARS-CoV-2 convalescent donor. These antibodies showed broad binding capacity and cross-neutralizing potency against various SARS-CoV-2 VOCs, including B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta), but failed to efficiently neutralize Omicron variant and its sublineages. Structural analysis revealed how Omicron sublineages, but not other VOCs, efficiently evade an antibody family cross-reactive against SARS-CoV-1 through their escape mutations. Further evaluation of a series of SARS-CoV-1/2-cross-reactive bNAbs showed a negative correlation between the neutralizing activities against SARS-CoV-1 and SARS-CoV-2 Omicron variant. Together, these results suggest the necessity of using cross-neutralization against SARS-CoV-1 and SARS-CoV-2 Omicron as criteria for rational design and development of potent pan-sarbecovirus vaccines and bNAbs.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / Severe acute respiratory syndrome-related coronavirus / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Med Virol Year: 2023 Document Type: Article Affiliation country: Jmv.28440

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / Severe acute respiratory syndrome-related coronavirus / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: J Med Virol Year: 2023 Document Type: Article Affiliation country: Jmv.28440